In vivo and in vitro experiments based on mouse colon cancer showed that shikonin disrupts PKM2 dimer and tetramer formation and induces the formation of macromolecular complexes, thereby inhibiting PKM2 activity and glycolytic flux and ameliorating colitis progression [116]. Here, PKM is linked to colitis.